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The APOA5 rs662799 polymorphism is
associated with dyslipidemia and the
severity of coronary heart disease in
Chinese women
Yanmei Wang1†, Zhan Lu1†, Jingxiao Zhang1, Yang Yang2, Jing Shen3, Xiaoming Zhang4 and Yongyan Song5*
Abstract
Background: The APOA5 rs662799 polymorphism has been widely reported regarding its associations with the
plasma lipid levels and the occurrence of coronary heart disease (CHD), whereas its relationship with the severity
of CHD has not yet been explored.
Methods: Four hundred and seventy-eight angiografically defined subjects (325 CHD patients and 153 CHD-free
controls) were enrolled in this study. The rs662799 polymorphism was genotyped, and the fasting lipid data were
collected for all participants. The severity of CHD was evaluated for the CHD patients by using Gensini scores.
Results: The variant C allele of the rs662799 polymorphism was associated with lower levels of HDL-C in CHD-free
women, and higher levels of TG and TG/HDL-C in women with CHD (P < 0.05 for all). The C allele was associated
with higher prevalence of dyslipidemia and higher levels of Gensini scores only in women (P < 0.05 for both), but
not in men. Multivariate linear regression analysis showed that the rs662799 polymorphism was independently
associated with the Gensini scores in women after adjustment for other potential CHD risk factors (Beta = 0.157,
95 % CI: 0.017–0.298, P = 0.028).
Conclusion: Our data indicate that the rs662799 polymorphism is associated with dyslipidemia and the severity of
CHD in Chinese women.
Keywords: APOA5, rs662799, Coronary heart disease, Lipid, Severity
Background
Coronary heart disease (CHD) is a major cause of death
in developed countries, and in some developing coun-
tries like China [1]. CHD is recognized as a multifactor-
ial disease, and dyslipidemia is closely associated with
the occurrence and development of CHD. It has been
demonstrated that dyslipidemia could account for
around 50 % of the population-attributable risk for CHD
[2]. Dyslipidemia is the elevation of plasma cholesterol,
triglycerides (TG), or both, or a reduction of high-
density lipoprotein cholesterol (HDL-C) that contributes
to the development of atherosclerosis. Of the dyslipid-
emia components, low-density lipoprotein cholesterol
(LDL-C) can directly deposit on the walls of blood
vessels to form atherosclerotic plaques and plasma
triglycerides exert their influence on CHD by increasing
the coagulation of blood [3]. Plasma cholesterol and TG
levels are known to be affected by many factors, among
which genetic polymorphisms in the apolipoprotein
genes were considered as the key factors [4].
The APOA1/C3/A4/A5 gene cluster, located on
chromosome 11q23, has been shown to be among the
most well characterized regions of the human genome
with reference to their dynamic associations with plasma
lipid levels [5]. APOA5 is a member of the APOA1/C3/
A4/A5 gene cluster and has been recognized as a key
regulator of TG metabolism [6]. This gene is exclusively
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expressed in liver, and its product, apolipoprotein AV
(apoAV), is combined with chylomicron, very low-
density lipoprotein (VLDL), high-density lipoprotein
(HDL), but not with low-density lipoprotein (LDL).
APOA5-knockout mice exhibited enhanced TG concen-
trations and conversely, APOA5-overexpressing mice
had lower TG levels than those control mice [7]. In
humans, a mutation in APOA5, which generates a trun-
cated apoAV, has been associated with severe hypertri-
glyceridemia [8] and hyperchylomicronemia [9]. The
underlying mechanisms by which apoAV reduces plasma
TG and cholesterol levels are not well-known so far.
However, experimental evidence supports the view that
this apolipoprotein may function as an activator of lipo-
protein lipase in the clearance of TG from the circula-
tion [10]. Furthermore, Vu-Dac et al. [11] reported that
APOA5 is a highly responsive peroxisome proliferator-
activated receptor alpha (PPARα)-target gene and fenofi-
brate, a plasma TG-lowering drug, can increase the
APOA5 expression in hepatocytes by stimulating the
PPARα pathway.
Of several variants within APOA5, a transition from T
to C located upstream of the promoter of this gene
results in a rs662799 polymorphism (also known as
-1131T>C). The rs662799 polymorphism has been ex-
tensively explored regarding its associations with plasma
lipid levels and the occurrence of CHD over the past de-
cades. In the literature, some studies demonstrated that
this polymorphism is associated with higher levels of TG
[12–25], total cholesterol (TC) [17] and LDL-C [18], and
lower levels of HDL-C [14–22]. A significant association
between this variant and the presence of CHD was also
reported in several studies [22–24, 26, 27]. However,
whether this polymorphism is associated with the sever-
ity of CHD has not been reported before.
Considering the association between the rs662799
polymorphism and dyslipidemia, it is logically plausible
to hypothesize a link between the rs662799 polymorph-
ism and the severity of CHD. In this study, a hospital-
based study with angiographically defined CHD patients
was conducted to systematically investigate the associa-
tions of the rs662799 polymorphism with dyslipidemia,
the occurrence and severity of CHD. Our study results
can provide the opportunity to elucidate the interrela-
tionships among the rs662799 polymorphism, dyslipid-
emia and CHD.
Results
The clinical and genetic characteristics of the study
population
As shown in Table 1, the CHD patients had higher
age (P = 0.001) and higher prevalence of dyslipidemia
(P = 0.011) and hypertension (P = 0.001) than the CHD-
free subjects in men; the CHD patients had higher age (P
< 0.001) and higher prevalence of menopause (P = 0.015),
dyslipidemia (P = 0.027), hypertension (P = 0.010) and dia-
betes (P = 0.042) than the CHD-free subjects in women.
The CHD patients had higher levels of apoB (P = 0.022),
TG/HDL-C (P = 0.036), TC/HDL-C (P = 0.001) and apoB/
apoAI (P = 0.002), and lower levels of HDL-C (P = 0.010)
and apoAI (P = 0.002) than the CHD-free subjects in men;
the CHD patients had higher levels of TG (P = 0.016), LDL-
C (P = 0.017), apoB (P = 0.020), TG/HDL-C (P = 0.015),
TC/HDL-C (P = 0.001), LDL-C/HDL-C (P < 0.001) and
apoB/apoAI (P = 0.004) than the CHD-free subjects in
women. The APOA5 rs662799 genotype or allele frequen-
cies did not differ significantly between the CHD patients
and the CHD-free subjects in both men and women.
Comparisons of the clinical and biochemical variables
among the APOA5 rs662799 genotypes
The demographic variables and lipid levels among the
genotypes of the rs662799 polymorphism are shown in
Table 2 for the CHD-free subjects and in Table 3 for the
CHD patients. HDL-C (P = 0.045) levels decreased or-
derly with the number of C alleles in CHD-free women.
TG (P = 0.009) and TG/HDL-C (P = 0.006) levels in-
creased orderly with the number of C alleles in women
with CHD. There were no significant differences in other
variables among the genotypes in both men and women.
The frequencies of the APOA5 rs662799 genotypes and
alleles in the non-dyslipidemic and dyslipdemic subjects
The distribution of the rs662799 genotypes and alleles
was significantly different between the non-dyslipidemic
subjects and dyslipidemic subjects in women (Table 4).
The frequencies of TC (P = 0.022) and CC (P = 0.050) ge-
notypes were higher in the dyslipidemic women than in
the non-dyslipidemic women. The C allele frequency was
higher in the dyslipidemic women than in the non-
dyslipidemic women (P < 0.001). There were no significant
differences in the distribution of genotypes or alleles be-
tween the non-dyslipidemic subjects and the dyslipidemic
subjects in men.
The Gensini score levels of the CHD patients according to
the APOA5 rs662799 genotypes
As shown in Fig. 1, the Gensini score levels increased
orderly with the number of C alleles in women patients
(P = 0.045). In men patients, the Gensini score levels
were similar among the genotypes.
Linear regression analysis of the APOA5 rs662799
polymorphism and other variables with the Gensini
scores in the CHD patients
The results of the linear regression analysis of the po-
tential CHD risk factors and the Gensini scores are
shown in Table 5. In men, univariate linear regression
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analyses were conducted and 9 viaribles [hyperten-
sion, TC, LDL-C, apoAI, apoB, Lp(a), TC/HDL-C,
LDL-C/HDL-C and apoB/apoAI] were found to be as-
sociated with the Gensini scores (P < 0.1 for all). Then
the 9 variables were taken into the stepwise multivariate
linear regression analysis and Lp(a) (P = 0.035) and apoB/
apoAI (P < 0.001) were found to be independently associ-
ated with the Gensini scores after controlling for the con-
founding variables including hypertension, TC, LDL-C,
apoAI, apoB, TC/HDL-C and LDL-C/HDL-C. In women,
9 viaribles [APOA5 rs662799 polymorphism, TC, LDL-C,
apoAI, apoB, Lp(a), TC/HDL-C, LDL-C/HDL-C and apoB/
apoAI] were found to be associated with the Gensini scores
in univariate linear regression analyses (P < 0.1 for all).
Then the 9 variables were taken into the stepwise multi-
variate linear regression analysis and APOA5 rs662799
polymorphism (P = 0.028), Lp(a) (P = 0.009) and apoB/
apoAI (P = 0.005) were found to be independently associ-
ated with the Gensini scores after controlling for the con-
founding variables including hypertension, TC, LDL-C,
apoAI, apoB, TC/HDL-C and LDL-C/HDL-C.
Discussion
The present study demonstrated that the rs662799
polymorphism was independently associated with the
severity of CHD in Chinese women patients. To our
knowledge, this is the first demonstration of a significant
association between the rs662799 polymorphism and the
severity of CHD, although the associations of the variant
with abnormal lipid profiles and the occurrence of CHD
have been reported in Chinese [22, 26, 27], Hungarian
[23] and Japanese [24].
Table 1 Clinical and genetic characteristics of the study population
Men Women
CHD-free (n = 81) CHD (n = 205) P CHD-free (n = 72) CHD (n = 120) P
Demographic characteristics
Age, years 59.88 ± 12.58 64.63 ± 9.51 0.001 59.14 ± 9.69 64.48 ± 8.30 <0.001
Weight, kg 65.35 ± 9.43 65.58 ± 8.54 0.863 59.65 ± 9.39 59.15 ± 9.09 0.902
BMI, kg/m2 23.58 ± 3.13 24.04 ± 3.03 0.311 24.26 ± 3.58 24.42 ± 3.68 0.507
Menopause, n (%) NA NA 62 (86.11) 115 (95.83) 0.015
Dyslipidemia, n (%) 49 (60.49) 155 (75.61) 0.011 32 (44.44) 73 (60.83) 0.027
Hypertension, n (%) 29 (35.80) 117 (57.07) 0.001 27 (37.50) 68 (56.67) 0.010
Diabetes, n (%) 9 (11.11) 27 (13.17) 0.636 6 (8.33) 23 (19.17) 0.042
Lipid levels
TG, mmol/L 1.27 ± 0.67 1.58 ± 1.31 0.056 1.42 ± 0.68 1.75 ± 1.10 0.016
TC, mmol/L 3.87 ± 1.01 4.13 ± 1.21 0.087 4.11 ± 1.03 4.40 ± 1.14 0.105
LDL-C, mmol/L 2.54 ± 1.85 2.61 ± 0.95 0.662 2.45 ± 0.77 2.77 ± 0.93 0.017
HDL-C, mmol/L 1.03 ± 0. 29 0.95 ± 0.23 0.010 1.11 ± 0.26 1.06 ± 0.24 0.118
ApoAI, g/L 1.08 ± 0.16 1.01 ± 0.20 0.002 1.13 ± 0.19 1.11 ± 0.18 0.394
ApoB, g/L 0.73 ± 0.24 0.81 ± 0.29 0.022 0.75 ± 0.23 0.84 ± 0.27 0.020
Lp(a), mg/L 264.04 ± 320.60 310.96 ± 332.45 0.140 239.74 ± 249.33 322.45 ± 340.38 0.087
TG/HDL-C 1.41 ± 1.03 1.82 ± 1.55 0.036 1.38 ± 0.83 1.85 ± 1.60 0.015
TC/HDL-C 3.94 ± 1.26 4.52 ± 1.35 0.001 3.75 ± 0.75 4.30 ± 1.31 0.001
LDL-C/HDL-C 2.55 ± 1.51 2.87 ± 1.10 0.052 2.24 ± 0.65 2.73 ± 1.08 <0.001
ApoB/apoAI 0.68 ± 0.25 0.85 ± 0.46 0.002 0.66 ± 0.19 0.78 ± 0.28 0.004
rs662799 Genotype frequency
TT, n (%) 43 (53.09) 103 (50.24) 0.751 42 (58.33) 63 (52.50) 0.351
TC, n (%) 33 (40.74) 90 (43.90) 28 (38.89) 51 (42.50)
CC, n (%) 5 (6.17) 12 (5.85) 2 (2.78) 6 (5.00)
rs662799 Allele frequency
T allele 0.735 0.722 0.761 0.778 0.738 0.376
C allele 0.265 0.278 0.222 0.263
CHD coronary heart disease, BMI body mass index, NA not available, TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-
density lipoprotein cholesterol, apoAI apolipoprotein AI, apoB apolipoprotein B
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The significant association between the rs662799 poly-
morphism and the severity of CHD was only observed in
women patients, but not in men patients. The gender-
specific effects of the rs662799 polymorphism on the se-
verity of CHD are not well understood. One reason
could be that the rs662799 polymorphism was associated
with dyslipidemia only in women (Table 4). The women
carrying one or more C alleles of the rs662799 poly-
morphism had higher prevalence of dyslipidemia than
those without this allele. It is logical to suppose that the
C allele carrying women experienced faster deposition of
lipids in the walls of coronary arteries and had severer
coronary stenosis than those without this allele. Another
raised question could be that why the rs662799 poly-
morphism was associated with higher prevalence of dys-
lipidemia only in women, but not in men in our study
population. This can be partly explained by the different
lifestyles between Chinese men and women. It has been
reported that the rs662799 polymorphism had inter-
action with lifestyles on the lipid levels in Asians [28].
The gender-specific effects of the rs662799 polymorph-
ism on lipid levels were also reported in other popula-
tions. In Turkish adults, Komurcu-Bayrak et al. [14].
demonstrated that the C carriers had higher fasting TG
levels in both genders, but lower HDL-C levels only in
women than the non-carriers. In our study population,
the CHD-free subjects were categorized into three sub-
groups [subjects with normal coronary arteries, subjects
with coronary atherosclerosis and subjects with minimal
coronary stenosis (stenosis < 50 %)] according to the
extent of coronary atherosclerosis. Interestingly, there
was a weak trend in the association between the
rs662799 polymorphism and the extent of coronary ath-
erosclerosis in CHD-free women, but not in men (data
not shown).
Our data did not support a significant association be-
tween the rs662799 polymorphism and the occurrence
of CHD, although an independent and significant associ-
ation was observed between the rs662799 polymorphism
and the severity of CHD in women. This result is beyond
our understanding since a series of case–control studies
demonstrated a significant association between the
rs662799 polymorphism and the occurrence of CHD
[22–24, 26, 27]. One of the reasons could be that the
control group in our study was not made up of healthy
individuals, but the subjects who underwent angiography
for suspected CHD. In the control group, 54.90 % of
them had normal coronary arteries, 33.99 % of them had
Table 2 Non-lipid variables and lipid levels of the CHD-free subjects by the APOA5 rs662799 genotypes
Men Women
TT genotype
(n = 43)
CT genotype
(n = 33)
CC genotype
(n = 5)
P TT genotype
(n = 42)
CT genotype
(n = 28)
CC genotype
(n = 2)
P
Non-lipid variables
Age, years 59.44 ± 12.99 59.88 ± 12.95 63.60 ± 5.89 0.787 59.00 ± 10.86 59.29 ± 7.72 64.50 ± 7.77 0.737
Weight, kg 64.00 ± 8.87 66.53 ± 9.73 69.00 ± 12.08 0.366 59.13 ± 10.76 59.46 ± 8.92 52.50 ± 3.53 0.635
BMI, kg/m2 23.30 ± 3.11 23.68 ± 2.96 25.28 ± 4.67 0.483 23.93 ± 4.08 24.48 ± 3.26 20.88 ± 0.85 0.404
Menopause, n (%) NA NA NA 36 (85.71) 24 (85.71) 2 (100.00 %) 0.784
Hypertension, n (%) 14 (32.56) 13 (39.39) 2 (40.00) 0.545 12 (28.57) 14 (50.00) 1 (50.00) 0.079
Diabetes, n (%) 4 (9.30) 5 (15.15) 0 (0.00) 0.898 2 (4.76) 4 (14.29) 0 (0.00) 0.305
Lipid variables
TG, mmol/L 1.20 ± 0.68 1.24 ± 0.50 2.07 ± 1.06 0.060 1.33 ± 0.65 1.58 ± 0.74 1.15 ± 0.23 0.288
TC, mmol/L 3.91 ± 1.08 3.77 ± 0.93 4.27 ± 0.68 0.554 4.30 ± 1.01 3.89 ± 1.05 3.51 ± 0.09 0.174
LDL-C, mmol/L 2.73 ± 2.44 2.26 ± 0.75 2.73 ± 0.63 0.550 2.59 ± 0.76 2.26 ± 0.77 2.10 ± 0.00 0.161
HDL-C, mmol/L 1.08 ± 0.35 0.98 ± 0.20 0.92 ± 0.25 0.264 1.18 ± 0.25 1.02 ± 0.24 0.92 ± 0.01 0.045
ApoAI, g/L 1.10 ± 0.15 1.06 ± 0.17 1.08 ± 0.17 0.705 1.16 ± 0.16 1.09 ± 0.22 0.99 ± 0.16 0.152
ApoB, g/L 0.71 ± 0.25 0.73 ± 0.24 0.85 ± 0.22 0.456 0.77 ± 0.25 0.73 ± 0.21 0.66 ± 0.10 0.680
Lp(a), mg/L 251.09 ± 323.39 280.68 ± 327.62 272.26 ± 321.52 0.926 236.26 ± 248.07 260.84 ± 271.67 211.95 ± 17.32 0.911
TG/HDL-C 1.29 ± 0.97 1.38 ± 0.78 2.62 ± 2.11 0.066 1.22 ± 0.78 1.63 ± 0.87 1.25 ± 0.25 0.131
TC/HDL-C 3.86 ± 1.43 3.91 ± 0.96 4.85 ± 1.24 0.247 3.69 ± 0.73 3.85 ± 0.82 3.83 ± 0.07 0.693
LDL-C/HDL-C 2.64 ± 1.92 2.36 ± 0.81 3.11 ± 0.92 0.506 2.23 ± 0.63 2.24 ± 0.69 2.29 ± 0.02 0.992
ApoB/apoAI 0.66 ± 0.27 0.69 ± 0.22 0.81 ± 0.22 0.424 0.66 ± 0.19 0.67 ± 0.17 0.69 ± 0.21 0.951
CHD coronary heart disease, BMI body mass index, NA not available, TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-
density lipoprotein cholesterol, apoAI apolipoprotein AI, apoB apolipoprotein B
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coronary atherosclerosis and 11.11 % of them had min-
imal coronary stenosis (stenosis < 50 %). Some other
studies [21, 29] which demonstrated negative association
between the rs662799 polymorphism and the occurrence
of CHD also enrolled the subjects with coronary athero-
sclerosis or minimal coronary stenosis as controls. On
the other hand, all the studies [22–24, 26, 27] which
concluded a positive association between the rs662799
polymorphism and the occurrence of CHD used healthy
individuals as controls.
The C allele frequency of the rs662799 polymorphism
was 0.26 in the present study population, which is
consistent with the ranges reported for other Asians, in-
cluding Chinese (0.29–0.39) [16, 17, 22, 26], Korean
(0.31) [15] and Japanese (0.33–0.35) [24], but is higher
than those reported for Caucasians (0.06–0.11) [13, 20,
21, 23]. The rs662799 polymorphism might have some
effects on the expression pattern of APOA5. The circu-
lating levels of apoAV protein were affected by the
rs662799 polymorphism in several studies, but the re-
sults were inconsistent [30, 31]. Kang et al. [30] demon-
strated that the C allele carriers had higher levels of
apoAV and TG than the non-carriers in type 2 diabetes
patients, whereas Jang et al. [31] reported that the C
Table 3 Non-lipid variables and lipid levels of the CHD patients by the APOA5 rs662799 genotypes
Men Women
TT genotype
(n = 103)
CT genotype
(n = 90)
CC genotype
(n = 12)
P TT genotype
(n = 63)
CT genotype
(n = 51)
CC genotype
(n = 6)
P
Non-lipid variables
Age, years 64.97 ± 9.34 64.17 ± 10.00 65.17 ± 7.60 0.827 65.17 ± 7.49 63.82 ± 9.20 62.40 ± 9.29 0.589
Weight, kg 65.71 ± 8.27 65.57 ± 9.13 64.00 ± 7.05 0.822 59.07 ± 8.14 58.59 ± 10.35 66.17 ± 5.63 0.156
BMI, kg/m2 24.17 ± 3.02 23.86 ± 3.10 23.81 ± 2.74 0.762 24.15 ± 3.06 24.55 ± 4.48 26.59 ± 1.83 0.298
Menopause, n (%) NA NA NA 62 (98.41) 48 (94.12) 5 (83.33) 0.068
Hypertension, n (%) 57 (55.34) 55 (61.11) 5 (41.47) 0.988 42 (66.7) 23 (45.10) 3 (50.00) 0.065
Diabetes, n (%) 16 (15.53) 10 (11.11) 1 (8.33) 0.303 13 (20.6) 9 (17.65) 1 (16.67) 0.674
Lipid variables
TG, mmol/L 1.36 ± 0.74 1.76 ± 1.73 1.83 ± 0.91 0.073 1.51 ± 0.86 1.96 ± 1.27 3.01 ± 1.55 0.009
TC, mmol/L 4.08 ± 1.18 4.24 ± 1.29 3.82 ± 0.84 0.448 4.31 ± 1.23 4.48 ± 1.03 4.44 ± 1.22 0.722
LDL-C, mmol/L 2.57 ± 0.91 2.71 ± 1.03 2.30 ± 0.61 0.307 2.70 ± 1.03 2.82 ± 0.79 2.94 ± 1.04 0.749
HDL-C, mmol/L 0.96 ± 0.20 0.95 ± 0.23 0.82 ± 0.24 0.124 1.09 ± 0.24 1.03 ± 0.24 0.91 ± 0.24 0.149
ApoAI, g/L 1.00 ± 0.16 1.02 ± 0.20 1.00 ± 0.15 0.861 1.13 ± 0.16 1.08 ± 0.20 1.11 ± 0.18 0.234
ApoB, g/L 0.80 ± 0.30 0.83 ± 0.30 0.77 ± 0.19 0.618 0.80 ± 0.27 0.88 ± 0.26 0.83 ± 0.33 0.255
Lp(a), mg/L 328.47 ± 362.37 271.98 ± 285.15 412.95 ± 371.18 0.271 369.27 ± 374.08 258.82 ± 274.92 441.90 ± 437.05 0.164
TG/HDL-C 1.53 ± 1.04 1.98 ± 1.81 2.60 ± 1.78 0.057 1.52 ± 1.00 2.14 ± 2.02 3.83 ± 2.73 0.006
TC/HDL-C 4.40 ± 1.41 4.59 ± 1.30 4.86 ± 1.17 0.411 4.07 ± 1.27 4.53 ± 1.33 4.99 ± 1.19 0.080
LDL-C/HDL-C 2.80 ± 1.16 2.95 ± 1.09 2.90 ± 0.68 0.665 2.57 ± 1.08 2.88 ± 1.07 3.26 ± 0.86 0.150
ApoB/apoAI 0.85 ± 0.45 0.87 ± 0.51 0.78 ± 0.19 0.808 0.72 ± 0.26 0.84 ± 0.29 0.86 ± 0.29 0.057
CHD coronary heart disease, BMI body mass index, NA not available, TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-
density lipoprotein cholesterol, apoAI apolipoprotein AI, apoB apolipoprotein B
Table 4 The distribution of the APOA5 rs662799 genotypes and alleles in the non-dyslipidemic and dyslipdemic subjects
Men Women
Non-dyslipidemic (n = 82) Dyslipidemic (n = 204) P Non-dyslipidemic (n = 87) Dyslipidemic (n = 105) P
Genotype frequency
TT, n (%) 45 (54.88) 101 (49.51) 0.280 59 (67.82) 46 (43.81) <0.001
TC, n (%) 34 (41.46) 89 (43.63) 28 (32.18) 51 (48.57)
CC, n (%) 3 (3.66) 14 (6.86) 0 (0.00) 8 (7.62)
Allele frequency
T allele 0.756 0.713 0.299 0.839 0.681 <0.001
C allele 0.244 0.287 0.161 0.319
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allele carriers had lower levels of apoAV but higher
levels of TG in healthy subjects and CHD patients.
ApoAV is combined with chylomicron, VLDL, HDL and
considered as a key regulator of TG metabolism. The
plasma levels of apoAV were reported to be negatively
associated with the TG levels [7–9]. Therefore, the asso-
ciation between the rs662799 polymorphism and the
severity of CHD could be mediated by apoAV and
hypertriglyceridemia.
Our findings should be considered in the context of
several potential limitations. Firstly, the small sample
size in each group may have limited the power to de-
tect a significant relationship. Secondly, the control
group was not made up of healthy individuals, but ra-
ther the subjects who underwent angiography with
suspected CHD at our hospital, which may have led
to a selection bias. However, it was difficult to enroll
healthy subjects who underwent coronary angiography
from general population. Thirdly, the patients in-
cluded in this study were exclusively Chinese Han
people, and therefore our findings may not apply to
other ethnic origins.
Conclusions
The rs662799 polymorphism is significantly associated
with dyslipidemia and the severity of CHD in Chinese
women, but further investigations with large sample size
and multi-ethnicities are required to validate the findings
from the present study.
Methods
Study participants
This study was designed as a hospital-based study. A
total of 478 consecutive and unrelated adult subjects
who underwent coronary angiography for suspected
CHD at the Department of Cardiology, the Affiliated
Hospital of North Sichuan Medical College (Nanchong,
China) were enrolled in the study between April 2014
and July 2015. Of these subjects, 325 subjects were diag-
nosed with CHD, while the rest 153 subjects were free
of CHD and considered as the control group. Subjects
taking lipid lowering drugs or the drugs that might affect
the glucose or lipid metabolism were excluded from the
study. In order to enlarge the sample size, those who
took the drugs which were thought not to affect plasma
lipid levels were still enrolled in this study. Subjects with
renal or hepatic dysfunction, active inflammatory dis-
ease, significant valvular disease, myocarditis, and malig-
nant disease were also excluded from the study. All the
subjects were Chinese Han people. The Han people are
the largest ethnic group in East Asia, constituting ap-
proximately 92 % of the population of Mainland China,
98 % of the population of Taiwan, and 74 % of the popu-
lation of Singapore. The tenets of the Declaration of
Helsinki were adhered to in all the procedures reported
in the article. The study protocol was reviewed and
approved by the Ethics Committee of the Affiliated
Hospital of North Sichuan Medical College. Signed in-
formed consent was provided by all the participants or
their guardians prior to their participation in the study.
Definitions
According to the Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in
Adults (ATP III), dyslipidemia was defined as the presence
of one or more of the following conditions: TG ≥
2.26 mmol/L, TC ≥ 6.22 mmol/L, LDL-C ≥ 4.14 mmol/L
and HDL-C < 1.04 mmol/L [32]. Smoking was defined as
regular cigarette smoking. Hypertension was defined as
the measurement of systolic/diastolic blood pressure
higher than 140/90 mmHg or active use of antihyperten-
sive drugs. Diabetes mellitus was defined as the fasting
glucose levels above 126 mg/dL or active use of antidia-
betic drugs or insulin. Body mass index (BMI) was calcu-
lated by dividing weight by height squared (kg/m2).
Biochemical measurement
Fasting blood samples were taken on the first morning of
the in-hospital day when no lipid-lowering drugs were used.
Samples were immediately shipped to the Department of
Fig. 1 The Gensini score levels of the CHD patients according to the
APOA5 rs662799 genotypes. The Gensini score levels were significantly
different among the women with different rs662799 genotypes (P< 0.05)
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Clinical Laboratory of the Affiliated Hospital of North
Sichuan Medical College for measurement of plasma lipids.
TG, TC, LDL-C and HDL-C were measured directly by en-
zymatic methods. ApoB, apoAI and Lp(a) were measured
by immunoturbidimetric assays. All the measurements
were carried out using an automatic clinical chemistry
analyzer (Beckman Coulter AU5800, USA). The lipoprotein
ratios were also calculated.
Diagnosis of CHD and evaluation of the severity of CHD
CHD was diagnosed in the patients who had angio-
graphic evidence of stenosis greater than 50 % in at least
one major coronary artery. Those with normal coronary
arteries, coronary atherosclerosis, or minimal stenosis
(less than 50 %) in any of the major coronary arteries
were considered as CHD-free control subjects. Two ex-
perienced cardiologists who were unaware of the clinical
history and laboratory results of the subjects performed
the coronary angiography. Standard coronary angiography
with at least four views of the left coronary system and
two views of the right coronary artery was performed
using the Judkins technique by Allura Xper FD20 (Philips
Medical Systems Nederland B.V. Netherlands). The
Gensini scoring system [33] was used to assess the severity
of CHD. In this system, the lumen narrowing of coronary
arteries is graded as 1 point for 1–25 % narrowing, 2
points for 26–50 % narrowing, 4 points for 51–75 % nar-
rowing, 8 points for 76–90 % narrowing, 16 points for
91–99 % narrowing, and 32 points for complete occlusion.
Each score is then multiplied by a factor that takes into ac-
count the importance of the lesion’s position in the coron-
ary arterial tree, for example, 5 points for the left main
coronary artery, 2.5 points for the proximal left anterior
descending branch (LAD) or proximal left circumflex
branch (LCX), 1.5 points for the middle LAD or middle
LCX, and 1 point for the distal LAD, distal LCX or right
coronary arteries. The Gensini score was calculated as the
sum of the scores for all coronary arteries.
Statistical analysis
Continuous data were presented as mean ± standard
deviation (SD) unless otherwise stated. Continuous vari-
ables were tested for normality, and log transformation
was conducted for those which did not conform to a
Table 5 Linear regression analysis of the Gensini scores (dependent variable) and the potential CHD risk factors (independent
variables) in CHD patients
Variables Men Women
Univariate linear
regression
P Multivariate linear
regression
P Univariate linear
regression
P Multivariate linear
regression
P
Beta (95 % CI) Beta (95 % CI) Beta (95 % CI) Beta (95 % CI)
APOA5
rs662799
−0.053 (−0.164–0.057) 0.342 0.187 (0.041–0.334) 0.013 0.157 (0.017–0.298) 0.028
Age 0.001 (−0.006–0.008) 0.777 0.008 (−0.003–0.018) 0.157
Weight 0.003 (−0.005–0.011) 0.530 −0.004 (−0.015–0.006) 0.391
BMI 0.018 (−0.004–0.041) 0.113 −0.007 (−0.003–0.019) 0.591
Menopause NA NA −0.031 (−0.474–0.411) 0.889
Hypertension 0.063 (0.013–0.112) 0.013 0.001 (−0.065–0.066) 0.981
Diabetes 0.106 (−0.091–0.303) 0.289 0.021 (−0.205–0.247) 0.854
TG −0.016 (−0.067–0.036) 0.556 0.031 (−0.047–0.109) 0.427
TC 0.059 (0.004–0.113) 0.035 0.074 (−0.003–0.151) 0.061
LDL-C 0.096 (0.027–0.165) 0.007 0.095 (0.001–0.189) 0.048
HDL-C −0.113 (−0.401–0.176) 0.442 −0.221 (−0.586–0.143) 0.232
ApoAI −0.384 (−0.717–
−0.051)
0.024 −0.841 (−1.330–
−0.352)
0.001
ApoB 0.372 (0.147–0.597) 0.001 0.430 (0.105–0.755) 0.010
Lp(a) 0.192 (0.038–0.346) 0.015 0.162 (0.012–0.312) 0.035 0.360 (0.152–0.568) 0.001 0.278 (0.071–0.486) 0.009
TG/HDL-C −0.001 (−0.046–0.043) 0.957 0.012 (−0.041–0.065) 0.647
TC/HDL-C 0.073 (0.025–0.121) 0.003 0.079 (0.012–0.146) 0.021
LDL-C/HDL-C 0.101 (0.042–0.160) 0.001 0.094 (0.013–0.175) 0.024
ApoB/apoAI 0.277 (0.137–0.416) <0.001 0.261 (0.124–0.398) <0.001 0.628 (0.332–0.923) <0.001 0.446 (0.137–0.756) 0.005
CHD coronary heart disease, BMI body mass index, NA not available, 95 % CI 95 % confidence interval, TG triglycerides, TC total cholesterol, ApoAI apolipoprotein
AI, ApoB apolipoprotein B, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein (a)
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normal distribution. The differences between the CHD
patients and the CHD-free subjects, the dyslipidemic
subjects and the non-dyslipidemic subjects, or among
the subjects with different genotypes were calculated by
Chi-square test for categorical variables, and one-way
ANOVA analysis for continuous variables. The Gensini
score levels among the patients with different genotypes
were compared by one-way ANOVA analysis. The P
values were adjusted by using the Bonferroni correction
in multiple comparisons of the variables among the
rs662799 genotypes. The associations between the
rs662799 polymorphism and the other potential CHD
risk factors and the Gensini scores were analyzed by uni-
variate and stepwise multivariate linear regression ana-
lyses; the variables with a P value less than 0.1 in
univariate analysis were taken into the multivariate ana-
lysis. The results of regression analysis were presented as
Beta with 95 % confidence interval (95 % CI). All P
values were two-tailed and the differences were consid-
ered as significant if P ≤ 0.05. All statistical analyses were
done by using 13.0 version SPSS (Chicago, IL, USA).
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